{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:36:13Z","timestamp":1782318973452,"version":"3.54.5"},"reference-count":26,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Vaccine hesitancy due to safety concerns is a hindrance to the success of vaccination campaigns. In February 2021, Trinidad and Tobago commenced its National COVID-19 Vaccination Program. Healthcare workers were among the first group to receive the ChAdOx1 nCoV-19 (Oxford\u2013AstraZeneca (Covishield, Serum Institute of India, Pune, India), the first COVID-19 vaccine available nationally. This study examined the safety of this vaccine in terms of the systemic and local adverse events following immunization reported by healthcare worker recipients. A cross-sectional study was conducted via a telephone questionnaire. Data concerning demographics, medical and COVID-19-related anamneses, and local and systemic side effects experienced within the first 48 h after receiving the first and second dose of this vaccine, respectively, were gathered. Among the 687 participants (male = 275; female = 412), prevalence of fever, body pain, chills, nausea, myalgia, headache, malaise, fatigue, and other systemic symptoms declined significantly 48 h after administration of the second dose compared to the first dose. Chi-square test and multiple logistic regression demonstrated the greater likelihood of younger recipients to report systemic symptoms compared to older recipients. Multiple logistic regression indicated that females were more likely to report headache, fatigue, and discomfort, and were less likely to report no symptoms, compared to males, after both doses. On average, recipients reported less local and systemic side effects 48 h after receiving the second dose compared to the first dose. The reported rate of occurrence of side effects was &lt;50% for most adverse events, which is consistent with the manufacturer\u2019s claims that the vaccine is safe. This study adds data on the safety of this vaccine in a population that has not been previously studied. The findings can inform public health policy efforts to lower vaccine hesitancy based on safety concerns surrounding the ChAdOx1 nCoV-19 vaccine across various groups in society, including healthcare workers.<\/jats:p>","DOI":"10.3390\/vaccines10030466","type":"journal-article","created":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T21:37:17Z","timestamp":1647812237000},"page":"466","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["ChAdOx1 nCoV-19 Vaccine Side Effects among Healthcare Workers in Trinidad and Tobago"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6891-1260","authenticated-orcid":false,"given":"Chavin D.","family":"Gopaul","sequence":"first","affiliation":[{"name":"The North Central Regional Health Authority, Eric Williams Medical Sciences Complex, Uriah Butler Highway, Champs Fleur 259807, Trinidad and Tobago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Ventour","sequence":"additional","affiliation":[{"name":"Anaesthesia & Intensive Care, Faculty of Medical Sciences, The University of the West Indies, St. Augustine 999183, Trinidad and Tobago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davlin","family":"Thomas","sequence":"additional","affiliation":[{"name":"The North Central Regional Health Authority, Eric Williams Medical Sciences Complex, Uriah Butler Highway, Champs Fleur 259807, Trinidad and Tobago"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/01410768211013437","article-title":"Assessing the long-term safety and efficacy of Covid-19 vaccines","volume":"1","author":"Majeed","year":"2021","journal-title":"J. R. Soc. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1136\/bmj.m4654","article-title":"Vaccinating the UK against Covid-19","volume":"371","author":"Majeed","year":"2020","journal-title":"BMJ J."},{"key":"ref_3","unstructured":"WHO (2021, August 31). Side-Effects of COVID-19 Vaccines 021. Available online: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/side-effects-of-COVID-19-vaccines\/."},{"key":"ref_4","first-page":"4780","article-title":"COVID-19: Norway investigates 23 deaths in frail elderly patients after vaccination","volume":"371","author":"Torjesen","year":"2021","journal-title":"BMJ J."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Riad, A., Pokorna, A., Attia, S., Klugarova, J., Koscik, M., and Klugar, M. (2021). Prevalence of Covid-19 vaccine side effects among healthcare workers in Czech Republic. J. Clin. Med., 10.","DOI":"10.3390\/jcm10071428"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gopaul, C., Ventour, D., Trotman, M., and Thomas, D. (2020). The Epidemiology Characteristics of Positive COVID-19 patients in Trinidad and Tobago. MedRxiv, Preprint.","DOI":"10.1101\/2020.08.06.20148288"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Gopaul, C., Ventour, D., and Thomas, D. (2020). Laboratory Predictors for COVID-19 ICU Admissions in Trinidad and Tobago. Research Square, Preprint.","DOI":"10.21203\/rs.3.rs-103394\/v1"},{"key":"ref_8","unstructured":"Central Statistical Office (2022, January 16). Provisional Mid Year Population Estimate by Age and Sex, 2005\u20132021, Available online: https:\/\/cso.gov.tt\/subjects\/population-and-vital-statistics\/population\/."},{"key":"ref_9","unstructured":"Ministry of Health, Trinidad and Tobago (2022, January 16). Statement from the Honourable Terence Deyalsingh, Minister of Health at the Media Conference to Advise of the First Confirmed (Imported) Case of COVID-19 in Trinidad and Tobago, Available online: http:\/\/www.health.gov.tt\/sitepages\/default.aspx?id=293."},{"key":"ref_10","unstructured":"Government of the Republic of Trinidad and Tobago Ministry of Health (2022, January 16). COVID-19 Novel Coronavirus, Available online: https:\/\/health.gov.tt\/covid-19\/covid-19-guidelines-and-regulations."},{"key":"ref_11","unstructured":"Government of the Republic of Trinidad and Tobago Ministry of Health (2022, January 16). Correction Re: COVID-19 Vaccines Received from Barbados, Available online: http:\/\/www.news.gov.tt\/content\/correction-re-covid-19-vaccines-received-barbados#.YeSJ2f7MJEZ."},{"key":"ref_12","unstructured":"Government of the Republic of Trinidad and Tobago Ministry of Health (2022, January 16). Trinidad and Tobago COVID-19 (Novel Coronavirus) Update #741, Available online: https:\/\/health.gov.tt\/covid-19-daily-update-monday-may-31st-2021."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"147","author":"Altman","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study","volume":"21","author":"Menni","year":"2021","journal-title":"Lancet Infect. Dis. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"n1088","DOI":"10.1136\/bmj.n1088","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study","volume":"373","author":"Bernal","year":"2021","journal-title":"BMJ J."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Hatmal, M.M., Al-Hatamleh, M.A., Olaimat, A.N., Hatmal, M., Alhaj-Qasem, D.M., Olaimat, T.M., and Mohamud, R. (2021). Side effects and perceptions following COVID-19 vaccination in Jordan: A randomized, cross-sectional study implementing machine learning for predicting severity of side effects. Vaccines, 9.","DOI":"10.3390\/vaccines9060556"},{"key":"ref_17","unstructured":"Madhi, S.A., Baillie, V., Cutland, C.L., Voysey, M., Koen, A.L., Fairlie, L., Padayachee, S.D., Dheda, K., Barnabas, S.L., and Bhorat, Q.E. (2021). Safety and efficacy of the ChAdOxI n-Cov-19 (AZDI 222) Covid-19 vaccine against the B.I.35I variant in South Africa. medRxiv, Preprint."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised controlled trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet J."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Alhazmi, A., Alamer, E., Daws, D., Hakami, M., Darraj, M., Abdelwahab, S., Maghfuri, A., and Algaissi, A. (2021). Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia. Vaccines, 9.","DOI":"10.3390\/vaccines9060674"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Abu-Hammad, O., Alduraidi, H., Abu-Hammad, S., Alnazzawi, A., Babkair, H., Abu-Hammad, A., Nourwali, I., Qasem, F., and Dar-Odeh, N. (2021). Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9060577"},{"key":"ref_22","unstructured":"AstraZeneca (2021, August 31). AZD1222 US Phase III Trial Met Primary Efficacy Endpoint in Preventing COVID-19 at Interim Analysis. Available online: https:\/\/www.astrazeneca.com\/."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Klugar, M., Riad, A., Mekhemar, M., Conrad, J., Buchbender, M., Howaldt, H.P., and Attia, S. (2021). Side effects of mRNA-based and viral vector-based COVID-19 vaccines among German healthcare workers. Biology, 10.","DOI":"10.3390\/biology10080752"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.51847\/bCwca2qGfP","article-title":"A cross-sectional survey of side effects after COVID-19 vaccination in Saudi Arabia: Male versus female outcomes","volume":"11","author":"Alghamdi","year":"2021","journal-title":"J. Adv. Pharm. Educ. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions. A systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/3\/466\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:38:41Z","timestamp":1760135921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/3\/466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["vaccines10030466"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10030466","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.11.09.21264627","asserted-by":"object"}]},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]}}}